Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Daiichi Sankyo to Receive METI’s Grant for Its Biopharmaceutical Production Facility Expansion
July 13, 2012
- Astellas to Develop Companion Diagnostic Agents in Collaboration with Other Companies: President Hatanaka
July 13, 2012
- Yoshindo to Develop Biopharmaceutical Business in 3 Steps: President Shimomura
July 13, 2012
- Taiho, Teikoku Form Alliance for Cancer Pain Reliever
July 12, 2012
- Teijin Pharma to Boost New Drug Ratio to More than 50%, Prepare “Post-Feburic” Products: President Arao
July 12, 2012
- Micro Marketing Method to Be Potentially Effective in Future: Ninomiya of Novartis Pharma
July 12, 2012
- Bayer HealthCare Initiates Multinational PIII Trial for Hemophilia A Treatment BAY94-9027
July 12, 2012
- Nippon Chemiphar Aiming to Boost Generic Drug Sales to 30 Billion Yen in FY2014: President Yamaguchi
July 12, 2012
- Shionogi Files Lawsuit against InterMune of US over Royalties Payment
July 12, 2012
- Astellas Transfers 2 APIs Including Psychotropic Agent to Maruishi
July 11, 2012
- Astellas Transfers 2 APIs Including Psychotropic Agent to Maruishi
July 11, 2012
- Halaven Fails to Meet Primary Endpoints vs Capecitabine in PIII Study: Eisai
July 11, 2012
- Suzuken to Offer Voluntary Early Retirement Program for Record 500 Employees
July 11, 2012
- BMKK Applies for Orencia SC Injection
July 11, 2012
- Takeda to Offer US Dollar Senior Notes for Repaying Debt for Nycomed Acquisition
July 11, 2012
- Taisho HD Acquires Mexican Pharmaceutical Companies to Enter OTC Drug Business
July 11, 2012
- Shionogi Launches First European Development Base
July 10, 2012
- Otsuka Licenses Digital Health Technology from Proteus of the US
July 10, 2012
- Astellas Launches RLS Treatment Regnite on July 10
July 10, 2012
- Pharmaceutical Companies Set Up Private Power Generators in Preparation for Planned Power Outages
July 9, 2012
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…